Search Results - Bone, R.N.

  • Showing 1 - 6 results of 6
Refine Results
  1. 1
    HSD88 Current Epcoritamab Plus Rituximab and Lenalidomide (R2) Perceptions for Patients With Relapsed/Refractory (R/R) Follicular Lymphoma (FL)

    HSD88 Current Epcoritamab Plus Rituximab and Lenalidomide (R2) Perceptions for Patients With Relapsed/Refractory (R/R) Follicular Lymphoma (FL) by Levine, E, Gentile, D, Swain, R, Bone, R.N., Jennings-Zhang, L., Jeune-Smith, Y., Feinberg, B

    Published in Value in health
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    HSD40 Therapeutic Decision-Making for Patients With Sickle Cell Disease (SCD) and How Research Findings Influence the Potential Use of Mitapivat

    HSD40 Therapeutic Decision-Making for Patients With Sickle Cell Disease (SCD) and How Research Findings Influence the Potential Use of Mitapivat by Sharpe, J, Brown, M, Gentile, D, Moffett, N, Bone, R.N., Jeune-Smith, Y., Hays, H, Feinberg, B

    Published in Value in health
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    HSD91 Practice Patterns and Patient Management Techniques Utilizing Patient-Reported Outcomes Among Community Oncologists

    HSD91 Practice Patterns and Patient Management Techniques Utilizing Patient-Reported Outcomes Among Community Oncologists by Miller, T.A., Brown, M., Zimmerman Savill, K., Bone, R.N., Jeune-Smith, Y., Feinberg, B.

    Published in Value in health
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    HSD56 Provider Perceptions Impacting Treatment Choice in Mantel Cell Lymphoma (MCL): An Analysis of the Shine Trial Evaluating Ibrutinib + Bendamustine and Rituximab (I+BR) Versus Bendamustine and Rituximab (BR) in First-Line (1L)

    HSD56 Provider Perceptions Impacting Treatment Choice in Mantel Cell Lymphoma (MCL): An Analysis of the Shine Trial Evaluating Ibrutinib + Bendamustine and Rituximab (I+BR) Versus... by Jeune-Smith, Y., Bone, R.N., Baljevic, M., Baird, S., Feinberg, B.

    Published in Value in health
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    HSD53 Community Oncologists’ Perceptions of Molecular Profiling: Insights into Precision Oncology Integration

    HSD53 Community Oncologists’ Perceptions of Molecular Profiling: Insights into Precision Oncology Integration by John, W, Bone, R.N., Leon, B, Lucht, S, Zimmerman Savill, K.M., Klink, A, Jeune-Smith, Y, Feinberg, B

    Published in Value in health
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    HSD49 Neoadjuvant Immunotherapy in Patients With Early-Stage, High-Risk, ER+/HER2– Breast Cancer: Physician Practices, Therapy Choice, and Barriers Among US Oncologists

    HSD49 Neoadjuvant Immunotherapy in Patients With Early-Stage, High-Risk, ER+/HER2– Breast Cancer: Physician Practices, Therapy Choice, and Barriers Among US Oncologists by Aggarwal, P, Van Doren, B, Jeune-Smith, Y., Jennings-Zhang, L., Bone, R.N., Sadeghi, S, Iyengar, NM, Feinberg, B

    Published in Value in health
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: